You are here

Induced pluripotent stem cell treatment set for its first human trial

Editage Insights | 2014年9月11日 | 6,408 浏览次数

Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. iPS cells, unlike embryonic stem cells, are developed from adult cells and are capable of becoming any type of cell in the body. The biggest advantage of iPS cells is that they can be genetically tailored to each individual and can be used to treat various diseases. For the first time, this technology will be used to treat age-related macular degeneration. Takashashi converted skin cells from her patient into iPS cells, which she then converted into retinal pigment epithelium cells; these cells will be transplanted into the patient’s damaged retina. A health-ministry committee has confirmed that this treatment will not provoke an immune reaction and mutations of any kind, and has approved its trial in humans. 

Read more in Nature


Update: The surgery was successfully performed on a Japanese woman in her 70s on September 12. See details here


《意得辑专家视点》深信知识需要开放给所有大众并传播,因此我们鼓励读者重复发表我们的内容,重复发表形式可为在线或印刷。我们采用知识共享(Creative Commons license),只要您遵守以下事项,即可免费重复发表我们的内容:
  • 作者信息:请尊重我们的作者,他们花费了时间精力为您撰写这些有价值的内容,重复发表时加注作者信息。
  • 意得辑专家视点:必须注明文章出自《意得辑专家视点》。
  • 表达您的情意:您可以加句“前往《意得辑专家视点》阅读全文”之类的话,啊,还有,别忘了加上文章链接。
  • 重复使用图片:要使用某些文章的图片必须事先取得许可,并加注图片原始出处。
  • 镶嵌代码:要重复使用这篇文章最简单的方式就是将下面的代码复制贴上您的页面!